Loading…
← CockpitCompetitor Analysis › 688578.SS Shanghai Allist Pharmaceuticals Co. Ltd. Class AOpen in the cockpit ↗

Shanghai Allist Pharmaceuticals Co. Ltd. Class A688578.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese oncology drugmaker known for its domestically developed EGFR lung-cancer targeted therapy.

≈ A China-focused AstraZeneca oncology unit, single-drug scaleMomentum weak 39
Mkt cap
$5.32B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$73.4M
20-day average traded
Fwd P/E
12.4×
forward earnings
ROIC−WACC
+36.7 pp
WACC 8.5%
Hurdle
-520 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥78.99
1D-1.2%
1W-6.1%
1M-6.5%
3M-33.8%
6M-14.4%
YTD-24.2%
1Y-22.5%
ATR %4.5%
52w lowhigh42.9% off high

What Shanghai Allist Pharmaceuticals does

Chinese oncology drugmaker known for its domestically developed EGFR lung-cancer targeted therapy.

Sells furmonertinib in China, where inclusion on the national insurance reimbursement list lifted prescriptions in exchange for lower prices. Outside Greater China, US-based ArriVent BioPharma holds the rights and is running overseas trials, so Allist is paid through milestones and royalties abroad rather than product sales.

In one line: A China-focused AstraZeneca oncology unit, single-drug scale.

Products and services

  • Furmonertinib (EGFR inhibitor)
  • Pipeline oncology candidates

Customers

  • Hospitals
  • Oncologists

Where it sits in the supply chain

  • Biotechnology
  • Small-molecule oncology drugs
  • Targeted therapy (EGFR inhibitors)

What could go right

  • Label expansion and earlier-line approvals
  • Ex-China licensing

What could go wrong

  • Single-drug revenue concentration
  • National price negotiations (VBP)

Moat: narrow (IP / patents). Patented, domestically developed EGFR inhibitor competing with imported drugs on the reimbursement list.

Headquarters: Shanghai, China · Founded: 2000 · Employees: 1,989

Named competitors

Shanghai Allist Pharmaceuticals at a glance

Size Shanghai Allist Pharmaceuticals (688578.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $5.32B, the 439th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥78.99 on 18 Nov 2026.

Performance Over six months the shares fell 14.4%, against +10.5% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 38.5% over the last twelve months (peer median +13.2%); the operating margin is 46.6% (peer median 19.4%).

Valuation It trades at 12.4× forward earnings against a peer median of 26.6× (4th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +520%, so the hurdle is -520 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 36.7 points above its cost of capital (8.5% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 112688578.SS 88
Six months, rebased to 100: Shanghai Allist Pharmaceuticals against the median of its 20 peers (local-currency closes).

Shanghai Allist Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.59BCN¥5.12BCN¥3.52BCN¥1.99BCN¥789M
Revenue growth—+46%+77%+152%—
Gross profitCN¥6.29BCN¥4.92BCN¥3.34BCN¥1.88BCN¥734M
EBITDAn/aCN¥2.34BCN¥1.51BCN¥590MCN¥64.9M
Net incomeCN¥2.91BCN¥2.19BCN¥1.43BCN¥644MCN¥131M
Free cash flowCN¥3.00BCN¥2.23BCN¥1.37BCN¥620M-CN¥10.3M
Capital expenditureCN¥81.0MCN¥186MCN¥270MCN¥67.9MCN¥144M
Total debtCN¥3.61MCN¥3.89MCN¥1.30MCN¥1.82MCN¥1.96M

Quarterly statements and history in the cockpit →

Shanghai Allist Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%4506MANELQDA603087326030PTCTGLAND600085ABBOTINDIA600079ERASGLAXOEMCURELGNDSUPNMIRM9995IONS688578.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Allist Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%10×20×30×40×4506LQDA603087326030PTCTIPCALABGLAND600079TVTXGLAXOEMCURESUPN9995688578.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Allist Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%4506LQDA326030PTCTGLAXOLGND688578.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Allist Pharmaceuticals is the large dot.

Shanghai Allist Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (688578.SS vs AZN.L vs 600276.SS vs 688235.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai Allist Pharmaceuticals 688578.SS$5.32B-14%+39%47%12.4×0.1%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
BeOne Medicines 688235.SS$45.5B+9%+25%18%59.7×19.1%
InnoCare Pharma 9969.HK$2.01B-10%+146%35%32.2×-2.0%
Hansoh Pharma 3692.HK$25.3B-3%+25%38%25.8×7.9%
Betta Pharmaceuticals 300558.SZ$2.70B-15%+16%11%38.0×23.2%
Dizal Pharmaceutical 688192.SS$4.02B+9%+720%69%7.8×-11.0%
Yuhan 000100.KS$4.11B-10%+8%6%40.4×n/a

How Shanghai Allist Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Allist Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure688578.SSPeer medianRank in peer set
1-month return-6.5%-1.7%4th lowest of 21
6-month return-14.4%+10.5%6th lowest of 21
Distance from 52-week high-42.9%-27.9%5th lowest of 21
Revenue growth (TTM)+38.5%+13.2%5th highest of 19
Operating margin46.6%19.4%3rd highest of 19
Forward P/E12.4×26.6×4th cheapest of 17
Growth the price implies (Req g, 7 yrs)0.1%6.6%4th least demanding of 16
Growth delivered (Del g)+519.6%+12.7%highest of 16
Hurdle (Req g minus delivered)-519.5 pp-2.5 ppleast demanding of 16
ROIC minus cost of capital+36.7 pp+2.6 pp3rd highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a

Questions

Who are Shanghai Allist Pharmaceuticals's main competitors?
Named competitors: AstraZeneca (AZN.L), Jiangsu Hengrui (600276.SS), BeiGene (688235.SS), InnoCare Pharma (9969.HK), Hansoh Pharmaceutical (3692.HK), Betta Pharmaceuticals (300558.SZ). The cockpit's measured peer set (industry) also includes Sumitomo Pharma (4506.T), Veradermics (MANE), Liquidia (LQDA), Gan & Lee Pharmaceuticals (603087.SS), SKBP (326030.KS), PTC Therapeutics (PTCT).
Is Shanghai Allist Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 12.4× against a peer median of 26.6×, 4th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +520%, so the hurdle is -520 pp: the price already allows for a slowdown.
How has Shanghai Allist Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -14.4% against +10.5% for the median peer; over one year -22.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.